Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Hanna Roberts

TitleInstructor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-PEDS

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Monroe DM, Hoffman M, Roberts HR, Hedner U. Progressive improvement in wound healing with increased therapy in haemophilia B mice. Haemophilia. 2013 Nov; 19(6):926-32. PMID: 23879625.
      View in: PubMed
    2. McDonald A, Hoffman M, Hedner U, Roberts HR, Monroe DM. Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B. J Thromb Haemost. 2007 Aug; 5(8):1577-83. PMID: 17663728.
      View in: PubMed
    3. Pathak A, Zhao R, Monroe DM, Roberts HR, Sheridan BC, Selzman CH, Stouffer GA. Thrombin generation in vascular tissue. J Thromb Haemost. 2006 Jan; 4(1):60-7. PMID: 16409451.
      View in: PubMed
    4. Gabriel DA, Li X, Monroe DM, Roberts HR. Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets. J Thromb Haemost. 2004 Oct; 2(10):1816-22. PMID: 15456494.
      View in: PubMed
    5. Allen GA, Wolberg AS, Oliver JA, Hoffman M, Roberts HR, Monroe DM. Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost. 2004 Mar; 2(3):402-13. PMID: 15009455.
      View in: PubMed
    6. Kjalke M, Ezban M, Monroe DM, Hoffman M, Roberts HR, Hedner U. High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol. 2001 Jul; 114(1):114-20. PMID: 11472355.
      View in: PubMed
    7. Wolberg AS, Kon RH, Monroe DM, Ezban M, Roberts HR, Hoffman M. Deencryption of cellular tissue factor is independent of its cytoplasmic domain. Biochem Biophys Res Commun. 2000 Jun 07; 272(2):332-6. PMID: 10833414.
      View in: PubMed
    8. Allen GA, Monroe DM, Roberts HR, Hoffman M. The effect of factor X level on thrombin generation and the procoagulant effect of activated factor VII in a cell-based model of coagulation. Blood Coagul Fibrinolysis. 2000 Apr; 11 Suppl 1:S3-7. PMID: 10850556.
      View in: PubMed
    9. Monroe DM, Hoffman M, Allen GA, Roberts HR. The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia. Semin Thromb Hemost. 2000; 26(4):373-7. PMID: 11092211.
      View in: PubMed
    10. Wolberg AS, Monroe DM, Roberts HR, Hoffman MR. Tissue factor de-encryption: ionophore treatment induces changes in tissue factor activity by phosphatidylserine-dependent and -independent mechanisms. Blood Coagul Fibrinolysis. 1999 Jun; 10(4):201-10. PMID: 10390120.
      View in: PubMed
    11. Chang JY, Monroe DM, Oliver JA, Roberts HR. TFPIbeta, a second product from the mouse tissue factor pathway inhibitor (TFPI) gene. Thromb Haemost. 1999 Jan; 81(1):45-9. PMID: 9974373.
      View in: PubMed
    12. Oliver JA, Monroe DM, Roberts HR, Hoffman M. Thrombin activates factor XI on activated platelets in the absence of factor XII. Arterioscler Thromb Vasc Biol. 1999 Jan; 19(1):170-7. PMID: 9888880.
      View in: PubMed
    13. Lusher JM, Roberts HR, Davignon G, Joist JH, Smith H, Shapiro A, Laurian Y, Kasper CK, Mannucci PM. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia. 1998 Nov; 4(6):790-8. PMID: 10028299.
      View in: PubMed
    14. Kjalke M, Monroe DM, Hoffman M, Oliver JA, Ezban M, Roberts HR. Active site-inactivated factors VIIa, Xa, and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation. Thromb Haemost. 1998 Oct; 80(4):578-84. PMID: 9798973.
      View in: PubMed
    15. Roberts HR, Monroe DM, Oliver JA, Chang JY, Hoffman M. Newer concepts of blood coagulation. Haemophilia. 1998 Jul; 4(4):331-4. PMID: 9873750.
      View in: PubMed
    16. Hoffman M, Monroe DM, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis. 1998 Mar; 9 Suppl 1:S61-5. PMID: 9819030.
      View in: PubMed
    17. Kjalke M, Monroe DM, Hoffman M, Oliver JA, Ezban M, Hedner U, Roberts HR. The effects of activated factor VII in a cell-based model for tissue factor-initiated coagulation. Blood Coagul Fibrinolysis. 1998 Mar; 9 Suppl 1:S21-5. PMID: 9819025.
      View in: PubMed
    18. Monroe DM, Hoffman M, Oliver JA, Roberts HR. A possible mechanism of action of activated factor VII independent of tissue factor. Blood Coagul Fibrinolysis. 1998 Mar; 9 Suppl 1:S15-20. PMID: 9819024.
      View in: PubMed
    19. Chang JY, Monroe DM, Oliver JA, Liles DK, Roberts HR. Cloning, expression, and characterization of mouse tissue factor pathway inhibitor (TFPI). Thromb Haemost. 1998 Feb; 79(2):306-9. PMID: 9493581.
      View in: PubMed
    20. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997 Dec; 99(3):542-7. PMID: 9401063.
      View in: PubMed
    21. Kjalke M, Oliver JA, Monroe DM, Hoffman M, Ezban M, Hedner U, Roberts HR. The effect of active site-inhibited factor VIIa on tissue factor-initiated coagulation using platelets before and after aspirin administration. Thromb Haemost. 1997 Oct; 78(4):1202-8. PMID: 9364985.
      View in: PubMed
    22. Chang JY, Monroe DM, Stafford DW, Brinkhous KM, Roberts HR. Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B. J Clin Invest. 1997 Aug 15; 100(4):886-92. PMID: 9259588.
      View in: PubMed
    23. Liles D, Landen CN, Monroe DM, Lindley CM, Read MS, Roberts HR, Brinkhous KM. Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B. Haemophilia. 1997 Jul; 3(3):231. PMID: 27214818.
      View in: PubMed
    24. Liles D, Landen CN, Monroe DM, Lindley CM, Read MS, Roberts HR, Brinkhous KM. Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B. Thromb Haemost. 1997 May; 77(5):944-8. PMID: 9184407.
      View in: PubMed
    25. Monroe DM, Hoffman M, Roberts HR. Transmission of a procoagulant signal from tissue factor-bearing cell to platelets. Blood Coagul Fibrinolysis. 1996 Jun; 7(4):459-64. PMID: 8839998.
      View in: PubMed
    26. Hoffman M, Monroe DM, Roberts HR. Cellular interactions in hemostasis. Haemostasis. 1996; 26 Suppl 1:12-6. PMID: 8904166.
      View in: PubMed
    27. Hoffman M, Monroe DM, Oliver JA, Roberts HR. Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood. 1995 Sep 01; 86(5):1794-801. PMID: 7655009.
      View in: PubMed
    28. Roberts HR, Monroe DM. Prothrombin times on deficient plasma reconstituted with factors IX and X. Am J Hematol. 1994 Nov; 47(3):246. PMID: 7942796.
      View in: PubMed
    29. Monroe DM, Roberts HR, Hoffman M. Platelet procoagulant complex assembly in a tissue factor-initiated system. Br J Haematol. 1994 Oct; 88(2):364-71. PMID: 7803283.
      View in: PubMed
    30. Chaing S, Clarke B, Sridhara S, Chu K, Friedman P, VanDusen W, Roberts HR, Blajchman M, Monroe DM, High KA. Severe factor VII deficiency caused by mutations abolishing the cleavage site for activation and altering binding to tissue factor. Blood. 1994 Jun 15; 83(12):3524-35. PMID: 8204879.
      View in: PubMed
    31. Hoffman M, Monroe DM, Roberts HR. Human monocytes support factor X activation by factor VIIa, independent of tissue factor: implications for the therapeutic mechanism of high-dose factor VIIa in hemophilia. Blood. 1994 Jan 01; 83(1):38-42. PMID: 8274750.
      View in: PubMed
    32. Lefkowitz JB, Monroe DM, Kasper CK, Roberts HR. Comparison of the behavior of normal factor IX and the factor IX Bm variant Hilo in the prothrombin time test using tissue factors from bovine, human, and rabbit sources. Am J Hematol. 1993 Jul; 43(3):177-82. PMID: 8352232.
      View in: PubMed
    33. Hoffman M, Monroe DM, Roberts HR. Platelet activation in patients with thrombotic thrombocytopenic purpura. Am J Hematol. 1993 Feb; 42(2):182-5. PMID: 7679878.
      View in: PubMed
    34. Hoffman M, Monroe DM, Roberts HR. A rapid method to isolate platelets from human blood by density gradient centrifugation. Am J Clin Pathol. 1992 Nov; 98(5):531-3. PMID: 1485606.
      View in: PubMed
    35. Hoffman M, Monroe DM, Roberts HR. Coagulation factor IXa binding to activated platelets and platelet-derived microparticles: a flow cytometric study. Thromb Haemost. 1992 Jul 06; 68(1):74-8. PMID: 1514177.
      View in: PubMed
    36. Rawala-Sheikh R, Ahmad SS, Monroe DM, Roberts HR, Walsh PN. Role of gamma-carboxyglutamic acid residues in the binding of factor IXa to platelets and in factor-X activation. Blood. 1992 Jan 15; 79(2):398-405. PMID: 1730085.
      View in: PubMed
    37. Ahmad SS, Rawala-Sheikh R, Monroe DM, Roberts HR, Walsh PN. Comparative platelet binding and kinetic studies with normal and variant factor IXa molecules. J Biol Chem. 1990 Dec 05; 265(34):20907-11. PMID: 2249997.
      View in: PubMed
    38. Monroe DM, Deerfield DW, Olson DL, Stewart TN, Treanor RE, Roberts HR, Hiskey RG, Pedersen LG. Calcium ion binding to human and bovine factor X. Blood Coagul Fibrinolysis. 1990 Dec; 1(6):633-40. PMID: 2133243.
      View in: PubMed
    39. Watzke HH, Lechner K, Roberts HR, Reddy SV, Welsch DJ, Friedman P, Mahr G, Jagadeeswaran P, Monroe DM, High KA. Molecular defect (Gla+14----Lys) and its functional consequences in a hereditary factor X deficiency (factor X "Vorarlberg"). J Biol Chem. 1990 Jul 15; 265(20):11982-9. PMID: 1973167.
      View in: PubMed
    40. McCord DM, Monroe DM, Smith KJ, Roberts HR. Characterization of the functional defect in factor IX Alabama. Evidence for a conformational change due to high affinity calcium binding in the first epidermal growth factor domain. J Biol Chem. 1990 Jun 25; 265(18):10250-4. PMID: 2355000.
      View in: PubMed
    41. Lozier JN, Monroe DM, Stanfield-Oakley S, Lin SW, Smith KJ, Roberts HR, High KA. Factor IX New London: substitution of proline for glutamine at position 50 causes severe hemophilia B. Blood. 1990 Mar 01; 75(5):1097-104. PMID: 2306516.
      View in: PubMed
    42. Telgt DS, Macik BG, McCord DM, Monroe DM, Roberts HR. Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor. Thromb Res. 1989 Dec 01; 56(5):603-9. PMID: 2626745.
      View in: PubMed
    43. Monroe DM, McCord DM, Huang MN, High KA, Lundblad RL, Kasper CK, Roberts HR. Functional consequences of an arginine180 to glutamine mutation in factor IX Hilo. Blood. 1989 May 01; 73(6):1540-4. PMID: 2713493.
      View in: PubMed
    44. Huang MN, Kasper CK, Roberts HR, Stafford DW, High KA. Molecular defect in factor IXHilo, a hemophilia Bm variant: Arg----Gln at the carboxyterminal cleavage site of the activation peptide. Blood. 1989 Feb 15; 73(3):718-21. PMID: 2563663.
      View in: PubMed
    45. Monroe DM, Sherrill GB, Roberts HR. Use of p-aminobenzamidine to monitor activation of trypsin-like serine proteases. Anal Biochem. 1988 Aug 01; 172(2):427-35. PMID: 3263815.
      View in: PubMed
    46. Turner AD, Monroe DM, Roberts HR, Porter NA, Pizzo SV. p-Amidino esters as irreversible inhibitors of factors IXa and Xa and thrombin. Biochemistry. 1986 Aug 26; 25(17):4929-35. PMID: 3490273.
      View in: PubMed
    47. Pizzo SV, Turner AD, Gonias SL, Monroe DM, Roberts HR, Porter NA. Nontoxic irreversible inhibitors of factors IXa, Xa, and thrombin: potential therapeutic agents for the in vivo regulation of thrombin generation and activity. Ann N Y Acad Sci. 1986; 485:199-203. PMID: 3494415.
      View in: PubMed
    48. Jones ME, Griffith MJ, Monroe DM, Roberts HR, Lentz BR. Comparison of lipid binding and kinetic properties of normal, variant, and gamma-carboxyglutamic acid modified human factor IX and factor IXa. Biochemistry. 1985 Dec 31; 24(27):8064-9. PMID: 3879187.
      View in: PubMed
    49. McGraw RA, Davis LM, Lundblad RL, Stafford DW, Roberts HR. Structure and function of factor IX: defects in haemophilia B. Clin Haematol. 1985 Jun; 14(2):359-83. PMID: 3899439.
      View in: PubMed
    50. Monroe DM, Noyes CM, Straight DL, Roberts HR, Griffith MJ. Activation of normal and abnormal human factor IX with trypsin. Arch Biochem Biophys. 1985 May 01; 238(2):490-6. PMID: 3873217.
      View in: PubMed
    51. Lusher JM, Eyster ME, Hilgartner MW, Kasper CK, Mannucci PM, Nilsson IM, Penner JA, Roberts HR. Panel discussion on the treatment of patients with factor VIII inhibitors. Prog Clin Biol Res. 1984; 150:323-35. PMID: 6431437.
      View in: PubMed
    52. Noyes CM, Griffith MJ, Roberts HR, Lundblad RL. Identification of the molecular defect in factor IX Chapel Hill: substitution of histidine for arginine at position 145. Proc Natl Acad Sci U S A. 1983 Jul; 80(14):4200-2. PMID: 6603618.
      View in: PubMed
    53. Braunstein KM, Noyes CM, Griffith MJ, Lundblad RL, Roberts HR. Characterization of the defect in activation of factor IX Chapel Hill by human factor XIa. J Clin Invest. 1981 Dec; 68(6):1420-6. PMID: 6976355.
      View in: PubMed
    54. Johnson CA, Chung KS, McGrath KM, Bean PE, Roberts HR. Characterization of a variant prothrombin in a patient congenitally deficient in factors II, VII, IX and X. Br J Haematol. 1980 Mar; 44(3):461-9. PMID: 7378310.
      View in: PubMed
    55. Chung KS, Goldsmith JC, Roberts HR. Isolation and characterization of factor IX Chapel Hill: comparison to normal human factor IX. Bibl Haematol. 1977; 44:68-74. PMID: 617785.
      View in: PubMed
    56. Pike IM, Yount WJ, Puritz EM, Roberts HR. Immunochemical characterization of a monoclonal G4,lambda human antibody to factor IX. Blood. 1972 Jul; 40(1):1-10. PMID: 4624720.
      View in: PubMed
    57. Brown PE, Hougie C, Roberts HR. The genetic heterogeneity of hemophilia B. N Engl J Med. 1970 Jul 09; 283(2):61-4. PMID: 5420360.
      View in: PubMed
    58. Saba HI, Roberts HR, Herion JC. The anticoagulant activity of lysosomal cationic proteins from polymorphonuclear leukocytes. J Clin Invest. 1967 Apr; 46(4):580-9. PMID: 6021205.
      View in: PubMed
    59. McLester WD, Roberts HR, Wagner RH. Use of an immunosorbent technique in the study of a PTC inhibitor: a new method for the investigation of blood coagulation. J Lab Clin Med. 1965 Oct; 66(4):682-7. PMID: 5843094.
      View in: PubMed
    Roberts's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (217) concept(s)
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)